As many as 1.02 crore shares changed hands in the block deal, according to data available on the exchanges.
Shares changed hands at an average price of ₹250 per share. The total transaction value is said to be ₹257 crore.
CNBC-TV18 had reported that global healthcare investment firm, OrbiMed Asia IV Mauritius FVCI Ltd intend to sell 2.27% stake in the company through block deals. The deal size stood at ₹256.8 crore.
Buyers and sellers in the transaction is not known officially.
As of the March-end quarter, OrbiMed Asia IV Mauritius FVCI Ltd had a 10.88% stake in the company.
Marksans Pharma posted a 15.6% year-on-year increase in consolidated net profit for the fourth quarter of FY25, rising to ₹90.5 crore from ₹78 crore. Revenue for the quarter grew 26.5% to ₹708.5 crore, compared to ₹560 crore in the same period last year.
Shares of Marksans Pharma Ltd. settled 1.32% lower on Tuesday at ₹250. The stock has tumbled nearly 20% so far in 2025.
First Published: Jun 11, 2025 9:01 AM IST
